We are excited to share that Jennifer Che, President and Managing Director of Eagle IP, will be attending the Life Sciences Patents Network (LSPN) North America Spring conference, held from April 29–30, 2026, at the Hyatt Regency Boston.

As a premier gathering for the global biopharma and medtech communities, LSPN Boston provides a vital platform for IP leaders to discuss the strategies and legal frameworks driving innovation in the life sciences. With her extensive background as  a medicinal chemist, US Patent Attorney, and Managing Director of a team of Chinese patent attorneys, Jennifer is uniquely positioned to engage with industry peers on the complex IP challenges, especially with respect to Asia, facing modern biotech companies.

If you are attending LSPN Boston and would like to discuss global IP strategy or specific developments in the Asian markets, Jennifer would welcome the opportunity to connect. Please contact us to schedule a meeting during the conference.

我們過去活動

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

2026年5月8日

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

2026年5月8日

Eagle IP to Attend INTA 2026 Annual Meeting in London

2026年5月2日

Pauli Wong to Share IP Strategy Insights at HKLSS Entrepreneurship Series 2026

2026年4月25日

Eagle IP and HKSTP Host AIPLA Women in IP Global Networking Event

2026年4月16日

Jennifer Che Shares China IP Insights at the Fordham IP Institute in New York

2026年4月8日

Recommended Insights

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

2025年2月4日
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
閱讀更多 >

What is the difference between an Invention Patent and a Utility Model Patent?

2021年8月13日
There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]
閱讀更多 >

Diagnostic Claims in China

2020年1月9日
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
閱讀更多 >

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
閱讀更多 >
Top crossarrow-right